|
|
|
|
|
Highlights from the 2023 European Society for Medical Oncology Annual Meeting
|
|
|
|
|
|
Proffered Paper Session 1 - Genitourinary Tumors, Non-Prostate
|
|
| Phase 3 THOR Study: Results of Erdafitinib vs Pembrolizumab in Pretreated Patients with Advanced or Metastatic Urothelial Cancer with Select FGFR Alterations
|
| Arlene O. Siefker-Radtke, MD
|
| Arlene Siefker-Radtke presents findings from the THOR study comparing erdafitinib to pembrolizumab in pretreated urothelial cancer patients with FGFR alterations. While the primary endpoint of superior overall survival with erdafitinib wasn't met, it showed a numerically better progression-free survival and objective response rate, demonstrating the potential for both treatments in this patient population.
|
|
|
|
|
|
| THOR-2 Cohort 1: Results of Erdafitinib vs Intravesical Chemotherapy for High-Risk Non-Muscle Invasive Bladder Cancer with Select FGFR Alterations Who Received Prior BCG Treatment
|
| James Catto, MB, ChB, FRCS(Urol), PhD, FRSB
|
| James Catto presents compelling findings from THOR-2 cohort 1 at #ESMO23, where oral erdafitinib significantly reduced the risk of recurrence or death by 72% compared to intravesical chemotherapy in high-risk NMIBC patients with FGFR mutations who had recurrent disease after BCG treatment and were ineligible for cystectomy. This study underscores the value of biomarker testing in NMIBC and the potential for targeted therapy in this population.
|
|
|
|
|
|
| Invited Discussant: Phase 3 THOR Study & THOR-2 Cohort 1
|
| Michiel S. Van der Heijden, MD, Ph.D.
|
| Michiel Van der Heijden's discussant presentation on the THOR and THOR-2 studies highlighted the significance of FGFR3 mutations in urothelial carcinoma. The THOR study demonstrated the potential of erdafitinib over chemotherapy in advanced urothelial carcinoma, but the combination of erdafitinib with pembrolizumab in THOR cohort 2 did not show a statistically significant difference in overall survival.
|
|
|
|
|
|
|
|
|
|
|
| The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan plus Enfortumab Vedotin as ≥ Second Line Therapy for Metastatic Urothelial Carcinoma
|
| Bradley McGregor, MD
|
| Bradley McGregor presents the Double Antibody Drug (DAD) conjugate phase I trial. This trial explored the combination of sacituzumab govitecan and enfortumab vedotin as a second-line or later therapy for metastatic urothelial carcinoma. This phase I trial included patients who had progressed after platinum and immunotherapy or were cisplatin-ineligible and had received one prior line of therapy.
|
|
|
|
|
|
| ICRA: Efficacy of Paclitaxel with Tremelimumab +/- Durvalumab in Metastatic Urothelial Carcinoma After Progression on Platinum Chemotherapy and Anti-PD-(L)1
|
| Sarah Einerhand
|
| Sarah Einerhand presented the ICRA trial which aimed to assess the efficacy of paclitaxel in combination with tremelimumab and, in some cases, durvalumab, for metastatic urothelial carcinoma patients who had relapsed after platinum-based chemotherapy and anti-PD-(L)1 treatment. The study found that the combination of paclitaxel and tremelimumab at a higher dose achieved an objective response rate of 26%, meeting the primary endpoint, while the combination with durvalumab or tremelimumab at a lower dose had an ORR of 8%.
|
|
|
|
|
|
| Invited Discussant: ICRA Trial & The Double Antibody Drug conjugate (DAD) Trial
|
| Thomas Powles, MBBS, MRCP, MD
|
| Thomas Powles discusses two significant trials in urothelial carcinoma treatment. The ICRA trial explored the potential of paclitaxel with tremelimumab +/- durvalumab for patients who progressed after platinum chemotherapy and anti-PD-(L)1. In the Double Antibody Drug conjugate (DAD) trial, sacituzumab govitecan plus enfortumab vedotin were tested as ≥ second-line therapy. Dr. Powles highlights complexities in these regimens and the promising role of antibody drug conjugates in urothelial carcinoma treatment. |
|
|
|
|
|
|
